Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ESIDRIX vs OXAYDO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption, leading to increased diuresis and decreased extracellular volume.
Oxycodone is a full opioid agonist with relative selectivity for mu-opioid receptors, although it can bind to kappa-opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect to analgesia for oxycodone.
Hypertension,Edema associated with congestive heart failure, cirrhosis, or renal disease
Management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate
25-50 mg orally once daily; may increase to 100 mg once daily or 50 mg twice daily for resistant edema.
Oral, 5-10 mg every 4-6 hours as needed for pain; maximum 60 mg per day.
Terminal elimination half-life is approximately 10-15 hours (mean 12 hours); clinical context: half-life prolonged in renal impairment, requiring dose adjustment.
Terminal elimination half-life is 3.5-5.5 hours for immediate-release oxycodone; clinically dose every 4-6 hours for sustained analgesia.
Not significantly metabolized; primarily excreted unchanged in urine.
Primarily hepatic via CYP3A4 and CYP2D6; major metabolites include noroxycodone (via CYP3A4) and oxymorphone (via CYP2D6). Conjugated with glucuronic acid.
Renal: approximately 70% excreted unchanged in urine; biliary/fecal: less than 10%.
Primarily renal as unchanged drug and metabolites; ~90% excreted in urine (approx 10% unchanged oxycodone, rest as noroxycodone and oxymorphone conjugates) and <10% in feces via biliary elimination.
Approximately 75% bound to plasma proteins, primarily albumin.
~45% bound to plasma proteins, primarily albumin.
Vd is 0.1-0.2 L/kg; indicates limited extravascular distribution consistent with hydrophilic properties.
2.6 L/kg; indicates extensive tissue distribution.
Oral: bioavailability is approximately 80-90%.
Oral bioavailability is 60-87% due to first-pass metabolism.
GFR 25-50 m L/min: administer every 12 hours; GFR 10-25 m L/min: administer every 24 hours; GFR <10 m L/min: not recommended due to ineffectiveness.
Cr Cl <30 m L/min: reduce dose by 50% and extend dosing interval to every 6 hours; avoid use in Cr Cl <15 m L/min.
Child-Pugh Class B or C: reduce dose by 50% or use with caution due to risk of electrolyte disturbances and hepatic encephalopathy.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: avoid use.
1-2 mg/kg orally once daily; maximum 50 mg/day.
Children (≥11 years): 5-10 mg every 4-6 hours as needed; maximum 60 mg/day. Children <11 years: not recommended due to high concentration.
Start at 12.5-25 mg orally once daily; monitor electrolytes and renal function; adjust dose based on response and tolerability.
Initiate at 3 mg every 6 hours; titrate cautiously due to increased sensitivity and risk of respiratory depression.
Not applicable
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS. See full prescribing information for complete boxed warning.
Hypokalemia,Hyperuricemia,Hypomagnesemia,Hypercalcemia,Orthostatic hypotension,Photosensitivity,Systemic lupus erythematosus exacerbation,Sulfonamide allergy cross-sensitivity
Addiction, abuse, and misuse,Life-threatening respiratory depression,Accidental ingestion (especially in children),Neonatal opioid withdrawal syndrome,Risks from concomitant use with benzodiazepines or other CNS depressants,Adrenal insufficiency,Severe hypotension,Gastrointestinal effects (constipation, ileus),Seizures in patients with seizure disorders,Serotonin syndrome with concomitant serotonergic drugs
Anuria,Hypersensitivity to hydrochlorothiazide or sulfonamide-derived drugs
Hypersensitivity to oxycodone or any component of the formulation,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus
Avoid high-sodium foods as they reduce antihypertensive efficacy. Limit potassium-rich foods (bananas, oranges) only if directed; hypokalemia risk is counteracted by high intake. Grapefruit juice may decrease HCTZ absorption; separate intake by 4 hours. Reduce alcohol intake to prevent additive hypotension.
Take OXAYDO on an empty stomach for consistent absorption; high-fat meals increase peak concentration by 25% and delay Tmax by 0.5-1 hour. Avoid grapefruit juice (inhibits CYP3A4) as it may elevate oxycodone levels.
First trimester: Limited human data; potential for fetal bradycardia and hypotension. Second and third trimesters: Increased risk of fetal hypotension, renal dysfunction, oligohydramnios, and skull ossification delays.
Pregnancy Category C. First trimester: Limited human data; animal studies show increased risk of neural tube defects at high doses. Second and third trimesters: Prolonged use may cause neonatal opioid withdrawal syndrome and respiratory depression. No specific teratogenicity pattern identified in humans.
Excreted in human milk; M/P ratio unknown. Due to potential for adverse effects (e.g., electrolyte disturbances), caution advised; avoid if possible, especially in preterm infants.
Enters breast milk; no specific M/P ratio reported. Use caution due to risk of infant sedation and respiratory depression. Monitor for signs of toxicity; alternative analgesics preferred.
No routine dose adjustment recommended based on pharmacokinetic changes; however, use lowest effective dose due to altered volume of distribution and clearance.
No specific dose adjustment recommended for pregnancy; increased clearance in second/third trimester may necessitate dose increase for adequate analgesia. Use lowest effective dose, avoid prolonged use; taper near term to minimize neonatal withdrawal.
Hydrochlorothiazide (HCTZ) in Esidrix may unmask diabetes (hyperglycemia), exacerbate gout (hyperuricemia), and cause hypokalemia (especially at high doses). Monitor electrolytes and renal function. Sunset yellow dye in tablets may cause allergic reactions in aspirin-sensitive patients.
OXAYDO is a single-entity oxycodone oral solution designed for rapid absorption; bioavailability is ~60-87% higher than oxycodone tablets due to high intestinal permeability. It is contraindicated with CYP3A4 inhibitors (e.g., ketoconazole) which can increase oxycodone levels. Monitor for respiratory depression, especially in opioid-naive patients. Each m L contains 7.5 mg oxycodone HCl, equivalent to 6.5 mg oxycodone base. Use with caution in patients with renal impairment (Cr Cl <30 m L/min).
Take in the morning to avoid nocturia.,Avoid prolonged sun exposure; use sunscreen as photosensitivity may occur.,Report signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat.,May increase blood sugar; monitor if diabetic.,Do not take with alcohol or other blood pressure medications without consulting doctor.
Take OXAYDO exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness, respiratory depression, coma, or death.,Do not drive or operate heavy machinery until you know how OXAYDO affects you; may cause dizziness or drowsiness.,Store securely away from children and pets; accidental ingestion can be fatal.,Do not crush, chew, or dissolve the capsules; swallow whole to avoid rapid release and overdose.,Report any difficulty breathing, confusion, or excessive sedation to your healthcare provider immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ESIDRIX vs OXAYDO, answered by our medical review team.
ESIDRIX is a Thiazide Diuretic that works by Thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption, leading to increased diuresis and decreased extracellular volume.. OXAYDO is a Opioid Analgesic that works by Oxycodone is a full opioid agonist with relative selectivity for mu-opioid receptors, although it can bind to kappa-opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect to analgesia for oxycodone.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ESIDRIX and OXAYDO depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ESIDRIX is: 25-50 mg orally once daily; may increase to 100 mg once daily or 50 mg twice daily for resistant edema.. The standard adult dose of OXAYDO is: Oral, 5-10 mg every 4-6 hours as needed for pain; maximum 60 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ESIDRIX and OXAYDO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ESIDRIX is classified as Category C. First trimester: Limited human data; potential for fetal bradycardia and hypotension. Second and third trimesters: Increased risk of fetal hypotension, renal dysfunction, oligohydr. OXAYDO is classified as Category C. Pregnancy Category C. First trimester: Limited human data; animal studies show increased risk of neural tube defects at high doses. Second and third trimesters: Prolonged use may c. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.